# Phase 1, Open-Label, Randomized, Study of the Safety and Pharmacokinetics of HU6

> **NCT07170189** · PHASE1 · COMPLETED · sponsor: **Rivus Pharmaceuticals, Inc.** · enrollment: 59 (actual)

## Conditions studied

- Overweight

## Interventions

- **DRUG:** HU6

## Key facts

- **NCT ID:** NCT07170189
- **Lead sponsor:** Rivus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-10-13
- **Primary completion:** 2025-12-04
- **Final completion:** 2025-12-04
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07170189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07170189, "Phase 1, Open-Label, Randomized, Study of the Safety and Pharmacokinetics of HU6". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07170189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*